The first objective is to evaluate the incidence of ovarian dysfunction after treatment with chemotherapy for childhood cancer or cancer at the reproductive age.
The second objective is to evaluate whether ovarian function is diminished by the following factors: specific chemotherapy group (e.g. alkylating agents, anthracyclins etc.) or specific chemotherapy agent (e.g. cyclophosphamide, daunorubicin etc.), dose of chemotherapy, age at time of treatment, time since treatment and surgery to the hypothalamic-pituitary-ovary axis.
This is a protocol.